{
  "docId": "019de072-f0cb-7745-907c-f9e6b87d2817",
  "docSlug": "e5afd111c5ca3d26ccce5d5b91b81d60",
  "documentTitle": "BioNTech | Investor Day Presentation Deck | 156 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 113,
  "pageCount": 120,
  "prevPage": 112,
  "nextPage": 114,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a process flow diagram to illustrate the trial design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f0cb-7745-907c-f9e6b87d2817/113",
  "deckHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817",
  "deckJsonHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817.json",
  "deckAnchorHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817#slide-113",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.71,
        "y": 0.18
      },
      "kind": "callout",
      "text": "US FDA Fast Track Designation and Orphan Drug Designation",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fc19dd8-a874-4614-9461-21f988db50f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.85,
        "x": 0.11,
        "y": 0.026
      },
      "kind": "diagram",
      "text": "Trial design flow showing patient selection, 2:1:1 randomization, treatment arms, and crossover upon disease progression.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "909688b6-74d4-4ac3-9b1b-0c19cbb32994",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.37,
        "y": 0.063
      },
      "kind": "list",
      "text": "Status: First patient dosed (June 2021), n=180, Global trial, Collaboration with Regeneron",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1308aa57-8d91-4cd4-b8b8-1a86d0f9fded",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.04,
        "y": 0.063
      },
      "kind": "list",
      "text": "Key endpoints: Primary (ORR), Efficacy (ORR, DoR, DCR, TTR, PFS, OS), Safety, Quality of life",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cba9be2-d1fb-44d0-af98-de5a2119abdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.7,
        "y": 0.063
      },
      "kind": "metric",
      "text": "Success measures: ORR=30%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cebf6d5-ea22-4d6a-a47d-9a3e2e22bf9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.04,
        "y": 0.092
      },
      "kind": "source-note",
      "text": "DCR, disease control rate; DoR, duration of response; ORR, overall response rate; OS, overall survival; PFS, progression free survival; R/R, relapsed/refractory; TTR, time to response. ClinicalTrials.gov: NCT04526899.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc6c1d53-17c2-4475-895f-5cb9f1952798",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "FixVac | BNT111 Phase 2 randomized trial ± cemiplimab in patients with anti-PD1-R/R melanoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bb46e1d-0e8f-4c55-96ac-fecf06fba58f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "54a6ff62-8de9-4cf4-b09f-de63044378b2",
      "evidence": "The slide presents a trial design, key endpoints, and success measures, which are typical components of the AIDA model (Attention, Interest, Desire, Action) to engage the audience and present a clear call to action.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 91,
      "beatId": "bf198718-eb7f-470f-aca0-0f710fbb4f37",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product Pipeline",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The presentation showcases BioNTech's product pipeline, including its oncology and infectious disease programs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}